NASH: latest news - GoINPHARMA
Saturday, 15 December 2018 - 21:46

NASH

Gilead and Intercept draw closer to launch new NASH therapies

The most debated issue at Liver Meeting, organized by AASLD (American Association for Study of Liver Diseases) and underway in San Francisco in these days, are probably therapies for non-alcoholic steatohepatitis. Four companies already have NASH therapies undergoing clinical trials–Intercept…

Pfizer, Novartis join forces to develop new NASH therapies

Pfizer and Novartis have jointly announced today that they have entered into an agreement aimed at developing new therapies for the treatment of non-alcoholic steatohepatitis (NASH), a business likely to deliver at least $35bn in sales, many experts say. Under…

Breathtec acquires Nash Pharmaceuticals

Canada-based group Breathtec Biomedical has announced it has acquired Nash Pharmaceuticals, another Canadian company with a pipeline of products still undergoing clinical trials in patients with Non-Alcoholic Steatohepatitis (NASH). NASH is a pathology spreading at an increasing rate, especially in the…

NASH sector heats up

Bloomberg yesterday reported that biotech Madrigal Pharmaceuticals  is weighing a sale after some early talks with large pharmaceutical groups. The news has made Madrigal’s shares jump by over 150% in the last month. Madrigal is a biotech based in Pennsylvania,…

Ionis sells NASH therapy to AstraZeneca for $300m

California-based Ionis Pharmaceuticals has announced it has licensed to AstraZeneca its investigational therapy Ionis-AZ6-2.5, developed to treat patients with Non-Alcoholic Steatohepatitis (NASH). This is the third therapy obtained from the partnership between the firms. Under the terms of the agreement,…

Investors reward Intercept Pharmaceuticals again

Intercept Pharmaceuticals is apparently experiencing a positive momentum, following the hardship over the last 8 months, which had caused shares to drop–they have fallen approximately 50% starting from September 2017. The positive phase reflects the New York-based company issuing new…

NASH, OK from Israel to test Oramed’s oral insulin

Oramed Pharmaceuticals, a biopharmaceutical company focusing on developing delivery solutions for oral drugs, has announced it has been granted an authorization by the Israeli regulatory authorities to conduct a clinical trial with its oral insulin ORMD-0801, in patients with NASH…

NASH: agreement between Boehringer Ingelheim and Dicerna Pharmaceuticals

Boehringer Ingelheim and Dicerna Pharmaceuticals, a company focusing on developing RNAi (RNA interference) therapies, have announced they have signed a research and license agreement in order to develop therapies addressing chronic liver diseases through Dicerna’s GalXC platform. The partnership will…

NASH: positive Phase II results for Gilead’s product

Gilead Science has announced the results from a Phase II randomized, placebo-controlled trial designed to assess GS-0976 in patients with NASH. The drug is an investigational oral product inhibiting ACC (Acetyl-CoA carboxylase). Two different dose regimens were tested in the…

NASH: Takeda signs agreement with HemoShear

Takeda Pharmaceutical and HemoShear Therapeutics, a private biotech company, have signed a collaboration agreement aimed at discovering and developing new therapies for liver diseases, including NASH. HemoShear’s REVEAL-Tx platform applies principles of physiological blood flow to tissue from patients. This…

NASH: new results from Allergan’s drug

Allergan announced new data from the CENTAUR Phase IIb study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis in adults with NASH. The results from a one-year treatment with cenicriviroc were released…

Boehringer Ingelheim/Pharmaxis start Phase IIa trial in NASH

Boehringer Ingelheim and Pharmaxis yesterday announced they have started a Phase IIa trial assessing BI 1467335 in NASH. The drug is an oral inhibitor which works by blocking leukocyte adhesion and tissue infiltration in inflammatory processes underlying the disease. NAFLD…

NASH and other liver diseases: study identifies new therapeutic targets

Researchers from KTH Royal Institute of Technology and Gothenburg University conducted a study on 46 human tissues, in order to identify the main liver-specific gene targets. The results were published in Molecular Systems Biology. The study mapped the metabolic changes…

Positive Phase II results for investigational BMS’ NASH drug

Novartis has reportedly hired Bank of America to work on two moves, of which it has already informed investors, related to subsidiary Alcon. The company, indeed, is weighing a carve out and a subsequent sale or IPO of Alcon. Alcon…

NASH, Allergan and Gilead, but Genfit and Intercept too

The NASH (nonalcoholic steatohepatitis) business has the potential to reach as much as $40bn—analysts say—and several companies are targeting it. Among these, Allergan and Gilead likely have the most promising pipelines in the business. However, Genfit and Intercept Pharmaceuticals are…

Gilead, positive results for selonsertib in NASH

Gilead announced positive results from the Phase II trial designed to assess GS-4997 (selonsertib), as monotherapy or in combination with simtuzumab, in NASH (nonalcoholic steatohepatitis), with moderate to severe liver fibrosis. The results are positive and will be presented at…

Second deal between BioLineRX and Novartis in NASH

Israel-based biotech BioLineRx saw its shares rising about 25% on announcement that it has entered into a second strategic cooperation deal with Novartis for NASH (nonalcoholic steatohepatitis) treatment. The first partnership between the two companies dates back to December 2014,…

What is stirring in NASH sector?

SunTrust Robinson Humphrey’s analysts have examined the reasons why NASH (non-alcoholic steatohepatitis) seems so interesting right now. According to evaluations by the financial team, M&A activity in the NASH space could increase, and the value of financial transactions could significantly…